Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) - Finn, RS; Boer, K; Bondarenko, I (Breast Cancer Res Treat, 2020)